Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 2/2019

01-02-2019 | Original Paper

The Role of Religious Service Attendance, Psychosocial and Behavioral Determinants of Antiretroviral Therapy (ART) Adherence: Results from HPTN 063 Cohort Study

Authors: Yusuf Ransome, Kenneth H. Mayer, Kiyomi Tsuyuki, Matthew J. Mimiaga, Carlos E. Rodriguez-Diaz, Kriengkrai Srithanaviboonchai, Ruth K. Friedman, Mohammed Limbada, Steven A. Safren, for the HIV Prevention Trials Network 063 Team

Published in: AIDS and Behavior | Issue 2/2019

Login to get access

Abstract

Early and sustained antiretroviral therapy (ART) adherence can suppress the HIV virus in individuals and reduce onward transmission of HIV in the population. Religiosity has been associated with better HIV clinical outcomes. Data are from a longitudinal, observational study of 749 HIV-infected individuals from Brazil, Zambia, and Thailand (HPTN 063). Ordered logistic regression assessed whether religious service attendance was associated with ART adherence (self-reported and plasma HIV-RNA) and moderated the association between alcohol problems and ART adherence. In each country, > 80% of participants reported high self-reported ART adherence (good/very good/excellent). Religious service attendance exceeded 85% but was statistically unrelated to adherence. In combined-country models, (p = 0.03) as alcohol problems increased, the probability of high self-reported ART adherence, as well as viral-load, became weaker at higher compared to low service attendance frequency. Future studies should evaluate spirituality variables and replicate the moderation analyses between religious attendance and alcohol problems.
Literature
1.
2.
Idler EL, editor. Religion as a social determinant of public health. New York: Oxford University Press; 2014.
3.
Williams DR, Sternthal MJ. Spirituality, religion and health: evidence and research directions. Med J Aust. 2007;186(10):S47–50.PubMed
4.
Nelson JM. Religion, spirituality, and physical health. In: Nelson JM, editor. Psychology, religion and spirituality. New York: Springer; 2009. p. 311–47.CrossRef
5.
Muñoz-Laboy M, Garcia J, Moon-Howard J, Wilson PA, Parker R. Religious responses to HIV and AIDS: understanding the role of religious cultures and institutions in confronting the epidemic. Glob Public Health. 2011;6(sup2):S127–31.PubMedCrossRef
6.
7.
Medved Kendrick H. Are religion and spirituality barriers or facilitators to treatment for HIV: a systematic review of the literature. AIDS Care. 2017;29(1):1–13.CrossRef
8.
Trickey A, May MT, Vehreschild J-J, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–56.CrossRef
9.
Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17–26.PubMedCrossRef
10.
Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, Shaukat M, et al. Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India. PLoS ONE. 2013;8(6):e66860.PubMedPubMedCentralCrossRef
11.
Kakinami L, de Bruyn G, Pronyk P, Mohapi L, Tshabangu N, Moshabela M, et al. The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa. AIDS Behav. 2011;15(4):823–31.PubMedCrossRef
12.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentralCrossRef
13.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–90.PubMedPubMedCentralCrossRef
14.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
15.
Günthard HF, Saag MS, Benson CA, Del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel. JAMA. 2016;316(2):191–210.PubMedPubMedCentralCrossRef
16.
Pargament KI, McCarthy S, Shah P, Ano G, Tarakeshwar N, Wachholtz A, et al. Religion and HIV: a review of the literature and clinical implications. South Med J. 2004;97(12):1201–10.PubMedCrossRef
17.
Bazant ES, Boulay M. Factors associated with religious congregation members’ support to people living with HIV/AIDS in Kumasi, Ghana. AIDS Behav. 2007;11(6):936–45.PubMedCrossRef
18.
Levin JS. Religion and health: is there an association, is it valid, and is it causal? Soc Sci Med. 1994;38(11):1475–82.PubMedCrossRef
19.
Ellison CG, Levin JS. The religion-health connection: evidence, theory, and future directions. Health Educ Behav. 1998;25(6):700–20.PubMedCrossRef
20.
Park J, Nachman S. The link between religion and HAART adherence in pediatric HIV patients. AIDS Care. 2010;22(5):556–61.PubMedCrossRef
21.
Van Wagoner N, Elopre L, Westfall AO, Mugavero MJ, Turan J, Hook EW. Reported church attendance at the time of entry into HIV care is associated with viral load suppression at 12 months. AIDS Behav. 2016;20(8):1706–12.PubMedCrossRef
22.
Dalmida SG, McCoy K, Koenig HG, Miller A, Holstad MM, Thomas T, et al. Examination of the role of religious and psychosocial factors in HIV medication adherence rates. J Relig Health. 2017;56(6):2144–61.PubMedCrossRef
23.
24.
Bluthenthal RN, Palar K, Mendel P, Kanouse DE, Corbin DE, Derose KP. Attitudes and beliefs related to HIV/AIDS in urban religious congregations: barriers and opportunities for HIV-related interventions. Soc Sci Med. 2012;74(10):1520–7.PubMedPubMedCentralCrossRef
25.
Wanyama J, Castelnuovo B, Wandera B, Mwebaze P, Kambugu A, Bangsberg DR, et al. Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda. AIDS. 2007;21(11):1486–7.PubMedCrossRef
26.
Finocchario-Kessler S, Catley D, Berkley-Patton J, Gerkovich M, Williams K, Banderas J, et al. Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: the role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDS. 2011;25(2):103–11.PubMedPubMedCentralCrossRef
27.
Vyas KJ, Limneos J, Qin H, Mathews WC. Assessing baseline religious practices and beliefs to predict adherence to highly active antiretroviral therapy among HIV-infected persons. AIDS Care. 2014;26(8):983–7.PubMedCrossRef
28.
Tumwine C, Neema S, Wagner G. Reasons why high religiosity can co-exist with and precipitate discontinuation of anti-retroviral therapy among different HIV clients in Uganda: an exploratory study. Religions. 2012;3(3):817–32.PubMedPubMedCentralCrossRef
29.
Pichon LC, Rossi KR, Ogg SA, Krull LJ, Griffin DY. Social support, stigma and disclosure: examining the relationship with HIV medication adherence among Ryan White Program Clients in the Mid-South USA. Int J Environ Res Public Health. 2015;12(6):7073–84.PubMedPubMedCentralCrossRef
30.
Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AKS, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STD. 2005;19(8):526–37.CrossRef
31.
32.
Parsons SK, Cruise PL, Davenport WM, Jones V. Religious beliefs, practices and treatment adherence among individuals with HIV in the southern United States. AIDS Patient Care STDs. 2006;20(2):97–111.PubMedCrossRef
33.
Kisenyi R, Muliira J, Ayebare E. Religiosity and adherence to antiretroviral therapy among patients attending a public hospital-based HIV/AIDS clinic in Uganda. J Relig Health. 2013;52(1):307–17.PubMedCrossRef
34.
Borders TF, Curran GM, Mattox R, Booth BM. Religiousness among at-risk drinkers: is it prospectively associated with the development or maintenance of an alcohol-use disorder? J Stud Alcohol Drugs. 2010;71(1):136–42.PubMedPubMedCentralCrossRef
35.
Lambert NM, Fincham FD, Marks LD, Stillman TF. Invocations and intoxication: does prayer decrease alcohol consumption? Psychol Addict Behav. 2010;24(2):209–19.PubMedCrossRef
36.
Parsons JT, Rosof E, Mustanski B. The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. Health Psychol. 2008;27(5):628–37.PubMedPubMedCentralCrossRef
37.
Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. Drug Alc Depend. 2016;167:103–11.CrossRef
38.
Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav. 2016;21(7):1825.CrossRef
39.
Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and Human Immunodeficiency Virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.PubMedPubMedCentralCrossRef
40.
Hahn JA, Woolf-King SE, Muyindike W. Adding fuel to the fire: alcohol’s effect on the HIV epidemic in Sub-Saharan Africa. Curr HIV/AIDS Rep. 2011;8(3):172.PubMedCrossRef
41.
42.
Kalichman SC, Simbayi LC, Vermaak R, Cain D, Smith G, Mthebu J, et al. Randomized trial of a community-based alcohol-related HIV risk-reduction intervention for men and women in Cape Town South Africa. Ann Behav Med. 2008;36(3):270–9.PubMedCrossRef
43.
Safren SA, Hughes JP, Mimiaga MJ, Moore AT, Friedman RK, Srithanaviboonchai K, et al. Frequency and predictors of estimated HIV transmissions and bacterial STI acquisition among HIV-positive patients in HIV care across three continents. J Int AIDS Soc. 2016;19(1):21096.PubMedPubMedCentralCrossRef
44.
Feldman B, Fredericksen R, Crane PK, Safren S, Mugavero M, Willig JH, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.PubMedPubMedCentralCrossRef
45.
Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.PubMedCrossRef
46.
Ojikutu BO, Pathak S, Srithanaviboonchai K, Limbada M, Friedman R, Li S, et al. Community cultural norms, stigma and disclosure to sexual partners among women living with HIV in Thailand, Brazil and Zambia (HPTN 063). PLoS ONE. 2016;11(5):e0153600.PubMedPubMedCentralCrossRef
47.
VanderWeele TJ, Li S, Tsai AC, Kawachi I. Association between religious service attendance and lower suicide rates among US women. JAMA Psychiatry. 2016;73(8):845–51.PubMedCrossRefPubMedCentral
48.
Ransome Y, Gilman SE. The role of religious involvement in black-white differences in alcohol use disorders. J Stud Alc Drugs. 2016;In Press.
49.
Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the multidimensional scale of perceived social support. J Pers Assess. 1990;55(3–4):610–7.PubMedCrossRef
50.
Saunders JB, Aasland OG, Babor TF, De la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791–804.PubMedCrossRef
51.
52.
Jaccard J, Wan CK, Turrisi R. The detection and interpretation of interaction effects between continuous variables in multiple regression. Multivar Behav Res. 1990;25(4):467–78.CrossRef
53.
Gunzler D, Chen T, Wu P, Zhang H. Introduction to mediation analysis with structural equation modeling. Shanghai Arch Psychiatry. 2013;25(6):390–4.PubMedPubMedCentral
54.
StataCorp. Stata statistical software: Release 14.0. College Station: StataCorp LP; 2015.
55.
56.
Miller WR. Researching the spiritual dimensions of alcohol and other drug problems. Addiction. 1998;93(7):979–90.PubMedCrossRef
57.
McGrath J. A glutton and a drunkard: what would Jesus drink? In: Robertson KC, editor. Religion and alcohol: Sobering thoughts. New York: Peter Lang Publishing Inc; 2004. p. 11–44.
58.
59.
60.
61.
Fiala WE, Bjorck JP, Gorsuch R. The religious support scale: construction, validation, and cross-validation. Am J Commun Psychol. 2002;30(6):761–86.CrossRef
62.
Cochran JK, Beeghley L, Bock EW. Religiosity and alcohol behavior: an exploration of reference group theory. Sociol Forum. 1988;3(2):256–76.CrossRef
63.
Malow R, Dévieux JG, Stein JA, Rosenberg R, Jean-Gilles M, Attonito J, et al. Depression, substance abuse and other contextual predictors of adherence to antiretroviral therapy (ART) among Haitians. AIDS Behav. 2013;17(4):1221–30.PubMedCrossRef
64.
Blashill AJ, Bedoya CA, Mayer KH, O’Cleirigh C, Pinkston MM, Remmert JE, et al. Psychosocial syndemics are additively associated with worse ART adherence in HIV-infected individuals. AIDS Behav. 2015;19(6):981–6.PubMedPubMedCentralCrossRef
65.
da Silva CM, Mendoza-Sassi RA, da Mota LD, Nader MM, de Martinez AMB. Alcohol use disorders among people living with HIV/AIDS in Southern Brazil: prevalence, risk factors and biological markers outcomes. BMC Infect Dis. 2017;17:263.PubMedPubMedCentralCrossRef
66.
Goodman MS. Comparison of small-area analysis techniques for estimating prevalence by race. Prev Chronic Dis. 2010;7(2):A33.PubMedPubMedCentral
67.
Trevino KM, Pargament KI, Cotton S, Leonard AC, Hahn J, Caprini-Faigin CA, et al. Religious coping and physiological, psychological, social, and spiritual outcomes in patients with HIV/AIDS: cross-sectional and longitudinal findings. AIDS Behav. 2010;14(2):379–89.PubMedCrossRef
68.
Zinnbauer BJ, Pargament KI, Cole B, Rye MS, Butter EM, Belavich TG, et al. Religion and spirituality: unfuzzying the fuzzy. J Sci Study Relig. 1997;36(4):549–64.CrossRef
69.
Powell LH, Shahabi L, Thoresen CE. Religion and spirituality: linkages to physical health. Am Psychol. 2003;58(1):36–52.PubMedCrossRef
70.
Tarakeshwar N, Khan N, Sikkema KJ. A relationship-based framework of spirituality for individuals with HIV. AIDS Behav. 2006;10(1):59–70.PubMedCrossRef
71.
Ironson G, Stuetzle R, Fletcher MA. An increase in religiousness/spirituality occurs after HIV diagnosis and predicts slower disease progression over 4 years in people with HIV. J Gen Intern Med. 2006;21(S5):S62–8.PubMedPubMedCentralCrossRef
Metadata
Title
The Role of Religious Service Attendance, Psychosocial and Behavioral Determinants of Antiretroviral Therapy (ART) Adherence: Results from HPTN 063 Cohort Study
Authors
Yusuf Ransome
Kenneth H. Mayer
Kiyomi Tsuyuki
Matthew J. Mimiaga
Carlos E. Rodriguez-Diaz
Kriengkrai Srithanaviboonchai
Ruth K. Friedman
Mohammed Limbada
Steven A. Safren
for the HIV Prevention Trials Network 063 Team
Publication date
01-02-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2206-2

Other articles of this Issue 2/2019

AIDS and Behavior 2/2019 Go to the issue

Original Paper

Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIV

Original Paper

Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China

Original Paper

The Effect of Partner Serostatus and Relationship Duration on HIV Medication Adherence

Original Paper

Pre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis

Original Paper

Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda

Original Paper

Paediatric ART Adherence in South Africa: A Comprehensive Analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits